Adherence to RIGHT Statement items (n=35) by each included NCCN guideline (n=48)
| Guideline | Version | Date of publication | RIGHT Statement domain | Total score (%) (n=35) | |||||
| Basic information (n=6) | Background (n=8) | Evidence (n=5) | Recommendations (n=7) | Review and quality assurance (n=2) | Funding and interests (n=4) | ||||
| Acute lymphoblastic leukaemia | 1.2018 | 3/12/2018 | 4.0 | 6.5 | 1.5 | 3.5 | 1.0 | 4.0 | 21 (60.0) |
| Acute myeloid leukaemia | 1.2018 | 2/7/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Amyloidosis | 1.2018 | 11/3/2017 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
| Anal | 1.2018 | 2/6/2018 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
| B cell | 2.2018 | 2/26/2018 | 4.0 | 6.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
| Basal cell | 1.2018 | 9/18/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Bladder | 3.2018 | 3/14/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Bone | 1.2018 | 8/29/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Breast | 4.2017 | 2/7/2018 | 4.5 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20 (57.1) |
| Cervical | 1.2018 | 3/20/2018 | 4.0 | 4.5 | 1.5 | 3.5 | 1.0 | 4.0 | 19 (54.3) |
| Chronic lymphocytic leukaemia | 1.2018 | 10/25/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Chronic myeloid leukaemia | 4.2018 | 3/14/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Central nervous system | 4.2018 | 1/24/2018 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
| Colon | 2.2018 | 3/14/2018 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
| Cutaneous B cell | 1.2018 | 9/18/2017 | 4.0 | 3.5 | 1.5 | 3.5 | 1.0 | 4.0 | 18 (51.4) |
| Dermato-protuberans | 1.2018 | 3/16/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Esophageal | 1.2018 | 3/16/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Gastric | 2.2018 | 9/26/2017 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
| Hairy cell | 1.2018 | 2/15/2018 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
| Head/neck | 1.2018 | 2/14/2018 | 4.0 | 4.0 | 1.5 | 3.5 | 1.0 | 4.0 | 18.5 (52.9) |
| Hepatobiliary | 1.2018 | 12/20/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Hodgkin | 3.2018 | 2/6/2018 | 4.0 | 5.5 | 1.5 | 3.5 | 1.0 | 4.0 | 20 (57.1) |
| Kaposi | 2.2018 | 2/26/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Kidney | 2.2018 | 1/19/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Myelodysplastic syndrome | 1.2018 | 9/18/2017 | 4.5 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20 (57.1) |
| Melanoma | 4.2018 | 2/12/2018 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
| Merkel | 2.2018 | 2/15/2018 | 4.5 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20 (57.1) |
| Mesothelioma | 2.2018 | 9/7/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Myeloproliferative Neoplasms | 3.2017 | 6/13/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Myeloma | 3.2018 | 2/21/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7%) |
| Neuroendocrine | 1.2018 | 11/9/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Non-small-cell lung | 2.2018 | 3/9/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Occult primary | 3.2017 | 9/11/2017 | 4.0 | 5.5 | 1.5 | 3.5 | 1.0 | 4.0 | 20 (57.1) |
| Ovarian | 1.2018 | 1/8/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Pancreatic | 2.2018 | 1/10/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Penile | 2.2018 | 3/8/2018 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
| Prostate | 1.2018 | 3/14/2018 | 4.0 | 6.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
| Rectal | 2.2018 | 1/17/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Sarcoma | 1.2018 | 10/31/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Squamous cell | 2.2018 | 10/5/2017 | 4.5 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20 (57.1) |
| Small-cell lung | 1.2018 | 9/6/2017 | 4.0 | 4.0 | 1.5 | 3.5 | 1.0 | 4.0 | 18.5 (52.9) |
| T cell | 3.2018 | 2/22/2018 | 5.0 | 6.0 | 1.5 | 3.5 | 1.0 | 4.0 | 21.5 (61.4) |
| Testicular | 2.2018 | 2/16/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Thymus | 2.2018 | 2/16/2018 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
| Thyroid | 2.2017 | 5/17/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Uterine | 1.2018 | 10/13/2017 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
| Vulvar | 1.2018 | 10/27/2017 | 5.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 20.5 (58.6) |
| Waldenstrom | 1.2018 | 3/7/2018 | 4.0 | 5.0 | 1.5 | 3.5 | 1.0 | 4.0 | 19.5 (55.7) |
NCCN, National Comprehensive Cancer Network; RIGHT, Reporting Items for practice Guidelines in HealThcare.